Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph(+) acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Chandra, Joya, Tracy, Jeannette, Loegering, David, Flatten, Karen, Verstovsek, Srdan, Beran, Miloslav, Gorre, Mercedes, Estrov, Zeev, Donato, Nicholas, Talpaz, Moshe, Sawyers, Charles, Bhalla, Kapil, Karp, Judith, Sausville, Edward, Kaufmann, Scott H.
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society of Hematology 2006
Témata:
Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895739/
https://ncbi.nlm.nih.gov/pubmed/16291594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-07-2966
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky